Published in Cancer Chemother Pharmacol on January 30, 2009
The development of immunoconjugates for targeted cancer therapy. Nat Rev Clin Oncol (2014) 1.49
Dual agent loaded PLGA nanoparticles enhanced antitumor activity in a multidrug-resistant breast tumor eenograft model. Int J Mol Sci (2014) 1.38
Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics (2014) 0.96
Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma. Mol Pharm (2012) 0.92
The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opin Drug Deliv (2010) 0.91
Ligand-targeted theranostic nanomedicines against cancer. J Control Release (2016) 0.77
Protocells: Modular Mesoporous Silica Nanoparticle-Supported Lipid Bilayers for Drug Delivery. Small (2016) 0.76
Design and in situ characterization of lipid containers with enhanced drug retention. Adv Mater (2011) 0.75
Nanotechnology and drug delivery: an update in oncology. Pharmaceutics (2011) 0.75
Drug delivery systems and combination therapy by using vinca alkaloids. Curr Top Med Chem (2015) 0.75
Preparation and physicochemical properties of vinblastine microparticles by supercritical antisolvent process. Int J Mol Sci (2012) 0.75
Phosphorus assay in column chromatography. J Biol Chem (1959) 60.56
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A (1998) 7.78
Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol (2005) 5.80
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 4.43
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev (1999) 4.02
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res (2002) 3.14
Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta (1993) 2.92
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol (2008) 2.72
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci (2008) 1.67
Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol (2000) 1.60
Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst (1989) 1.60
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer (2000) 1.51
Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res (2005) 1.51
Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets (2004) 1.48
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res (2006) 1.43
Ligand-targeted liposomal anticancer drugs. Prog Lipid Res (2003) 1.37
Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst (1996) 1.21
Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol (2007) 1.20
Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett (1992) 1.19
Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta (1985) 1.18
Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer (1995) 1.16
Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release (2005) 1.12
Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J Pharmacol Exp Ther (2000) 1.08
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta (2002) 1.08
Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol (1993) 1.07
Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog (2005) 1.06
Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med Chem (2006) 1.05
Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother (2003) 1.05
Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta (1997) 1.04
Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res (1990) 1.04
Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta (2006) 1.04
Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res (2005) 1.03
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer (2006) 1.01
Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta (2002) 1.00
Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro. Cancer Res (1979) 0.99
Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog (2005) 0.98
Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol (1997) 0.98
Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug Target (1996) 0.96
Phase I study of liposomal vincristine. J Clin Oncol (1999) 0.95
Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol (1988) 0.94
Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res (2004) 0.93
Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci (2005) 0.92
Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clin Cancer Res (2004) 0.91
Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta (2007) 0.90
Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. J Clin Pharmacol (2006) 0.88
Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Hum Exp Toxicol (1996) 0.88
Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line. Biochemistry (2000) 0.81
Sphingomyelin/cholesterol liposomal vincristine: a new formulation for an old drug. Expert Opin Biol Ther (2006) 0.79
The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity. Cancer Chemother Pharmacol (1996) 0.78
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer (2006) 5.47
Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem (2006) 4.59
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 4.43
Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol (2005) 3.66
Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res (2009) 3.40
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res (2002) 3.14
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol (2005) 3.12
Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res (2006) 2.83
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol (2006) 2.66
Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids. PLoS One (2007) 2.28
Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev (2008) 2.12
Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res (2004) 2.10
The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther (2006) 2.10
Breast cancer growth prevention by statins. Cancer Res (2006) 2.09
Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg (2005) 2.07
First pregnancy events and future breast density: modification by age at first pregnancy and specific VEGF and IGF1R gene variants. Cancer Causes Control (2014) 2.05
A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res (2004) 2.00
Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol (2005) 1.78
Antibodies from phage antibody libraries. J Immunol Methods (2004) 1.75
Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc (2005) 1.74
Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine (2002) 1.69
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci (2008) 1.67
Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res (2011) 1.62
Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis (2002) 1.61
Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol (2004) 1.61
A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol (2006) 1.59
Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer (2007) 1.57
Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res (2005) 1.51
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res (2010) 1.50
Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci (2002) 1.48
Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets (2004) 1.48
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol (2007) 1.48
Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol (2004) 1.45
Characterization of biofilm formation by clinical isolates of Mycobacterium avium. J Med Microbiol (2003) 1.45
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res (2006) 1.43
Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun (2009) 1.43
Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat (2011) 1.39
Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res (2005) 1.38
Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res (2006) 1.36
Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One (2009) 1.35
Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett (2008) 1.34
Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res (2003) 1.33
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol (2007) 1.32
Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods Mol Biol (2009) 1.32
Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer (2008) 1.32
Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol (2006) 1.29
Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS One (2010) 1.28
Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat (2003) 1.27
Targeted quantitation of site-specific cysteine oxidation in endogenous proteins using a differential alkylation and multiple reaction monitoring mass spectrometry approach. Mol Cell Proteomics (2010) 1.26
Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol (2006) 1.26
Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res (2006) 1.26
Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg (2008) 1.25
Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β. J Clin Invest (2011) 1.25
Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res (2004) 1.25
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res (2008) 1.25